{"FP": [{"generated": ["extensive metabolizer", "AUC", "concentration-time curve", "poor metabolizer"], "gold": ["AUC: concentration-time curve"], "text": "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer."}, {"generated": ["extensive metabolizer", "AUC", "concentration-time curve", "poor metabolizer"], "gold": ["AUC: concentration-time curve"], "text": "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer."}, {"generated": ["extensive metabolizer", "AUC", "concentration-time curve", "poor metabolizer"], "gold": ["AUC: concentration-time curve"], "text": "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer."}, {"generated": ["extensive metabolizer", "AUC", "concentration-time curve", "poor metabolizer"], "gold": ["AUC: concentration-time curve"], "text": "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer."}, {"generated": ["biotransformation", "cytochrome P450 (CYP450) family of enzymes", "xenobiotics", "endogenous substances"], "gold": [], "text": "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14]."}, {"generated": ["biotransformation", "cytochrome P450 (CYP450) family of enzymes", "xenobiotics", "endogenous substances"], "gold": [], "text": "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14]."}, {"generated": ["biotransformation", "cytochrome P450 (CYP450) family of enzymes", "xenobiotics", "endogenous substances"], "gold": [], "text": "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14]."}, {"generated": ["biotransformation", "cytochrome P450 (CYP450) family of enzymes", "xenobiotics", "endogenous substances"], "gold": [], "text": "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14]."}, {"generated": ["K_A (non-targeted approach", "time course", "metabolites", "Linear regression analysis"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["K_A (non-targeted approach", "time course", "metabolites", "Linear regression analysis"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["K_A (non-targeted approach", "time course", "metabolites", "Linear regression analysis"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["K_A (non-targeted approach", "time course", "metabolites", "Linear regression analysis"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["pharmacodynamics", "St John's wort", "CYP2C9", "gliclazide", "genotype", "type 2 diabetes", "pharmacokinetics"], "gold": [], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": ["pharmacodynamics", "St John's wort", "CYP2C9", "gliclazide", "genotype", "type 2 diabetes", "pharmacokinetics"], "gold": [], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": ["pharmacodynamics", "St John's wort", "CYP2C9", "gliclazide", "genotype", "type 2 diabetes", "pharmacokinetics"], "gold": [], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": ["pharmacodynamics", "St John's wort", "CYP2C9", "gliclazide", "genotype", "type 2 diabetes", "pharmacokinetics"], "gold": [], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": ["pharmacodynamics", "St John's wort", "CYP2C9", "gliclazide", "genotype", "type 2 diabetes", "pharmacokinetics"], "gold": [], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": ["pharmacodynamics", "St John's wort", "CYP2C9", "gliclazide", "genotype", "type 2 diabetes", "pharmacokinetics"], "gold": [], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": ["pharmacodynamics", "St John's wort", "CYP2C9", "gliclazide", "genotype", "type 2 diabetes", "pharmacokinetics"], "gold": [], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": ["Park et al."], "gold": [], "text": "Park et al."}, {"generated": ["Antinuclear antibody (ANA)", "smooth muscle antibody"], "gold": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "text": "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["categorical variables", "ratios", "baseline characteristics", "mean \u00b1 SD", "continuous variables"], "gold": ["AUC"], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["categorical variables", "ratios", "baseline characteristics", "mean \u00b1 SD", "continuous variables"], "gold": ["AUC"], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["categorical variables", "ratios", "baseline characteristics", "mean \u00b1 SD", "continuous variables"], "gold": ["AUC"], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["categorical variables", "ratios", "baseline characteristics", "mean \u00b1 SD", "continuous variables"], "gold": ["AUC"], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["categorical variables", "ratios", "baseline characteristics", "mean \u00b1 SD", "continuous variables"], "gold": ["AUC"], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["conceptualization"], "gold": [], "text": "Conceptualization, M.-K.C."}, {"generated": ["metabolic rate of AC", "maximum plasma concentration", "Rat liver microsomes"], "gold": [], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": ["metabolic rate of AC", "maximum plasma concentration", "Rat liver microsomes"], "gold": [], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": ["metabolic rate of AC", "maximum plasma concentration", "Rat liver microsomes"], "gold": [], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": ["half-life (t)", "SD", "mean"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["half-life (t)", "SD", "mean"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["half-life (t)", "SD", "mean"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["P < 0.0001", "p-value"], "gold": [], "text": "***P < 0.0001."}, {"generated": ["P < 0.0001", "p-value"], "gold": [], "text": "***P < 0.0001."}, {"generated": ["treatments", "7 \u00b1 1-day washout period", "in-between"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["treatments", "7 \u00b1 1-day washout period", "in-between"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["treatments", "7 \u00b1 1-day washout period", "in-between"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["Supplement", "Presupplementation", "Postsupplementation", "Phenotypic Ratios", "CYP"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["Supplement", "Presupplementation", "Postsupplementation", "Phenotypic Ratios", "CYP"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["Supplement", "Presupplementation", "Postsupplementation", "Phenotypic Ratios", "CYP"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["Supplement", "Presupplementation", "Postsupplementation", "Phenotypic Ratios", "CYP"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["Supplement", "Presupplementation", "Postsupplementation", "Phenotypic Ratios", "CYP"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["CYP2E1 responsivity", "allyl sulfide content"], "gold": [], "text": "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements."}, {"generated": ["CYP2E1 responsivity", "allyl sulfide content"], "gold": [], "text": "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements."}, {"generated": ["Pregnancy", "histories of hypersensitivity to quinine or similar agents", "adverse side effects from taking G. kola seeds", "breastfeeding"], "gold": [], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["Pregnancy", "histories of hypersensitivity to quinine or similar agents", "adverse side effects from taking G. kola seeds", "breastfeeding"], "gold": [], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["Pregnancy", "histories of hypersensitivity to quinine or similar agents", "adverse side effects from taking G. kola seeds", "breastfeeding"], "gold": [], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["Pregnancy", "histories of hypersensitivity to quinine or similar agents", "adverse side effects from taking G. kola seeds", "breastfeeding"], "gold": [], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "INR data", "time data", "S-warfarin concentration"], "gold": ["INR", "prothrombin complex activity (PCA"], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "INR data", "time data", "S-warfarin concentration"], "gold": ["INR", "prothrombin complex activity (PCA"], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "INR data", "time data", "S-warfarin concentration"], "gold": ["INR", "prothrombin complex activity (PCA"], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "INR data", "time data", "S-warfarin concentration"], "gold": ["INR", "prothrombin complex activity (PCA"], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "INR data", "time data", "S-warfarin concentration"], "gold": ["INR", "prothrombin complex activity (PCA"], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["population PKPD parameter estimates", "warfarin"], "gold": [], "text": "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3."}, {"generated": ["population PKPD parameter estimates", "warfarin"], "gold": [], "text": "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3."}, {"generated": ["financial support"], "gold": [], "text": "Apoio financeiro: Nenhum."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["deviation of \u00b11 day"], "gold": [], "text": "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted."}, {"generated": ["group 1: CC", "group 2: herbal mixture", "n: number of participants in each group", "group 3: CC with herbal mixture", "participants", "groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 1: CC", "group 2: herbal mixture", "n: number of participants in each group", "group 3: CC with herbal mixture", "participants", "groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 1: CC", "group 2: herbal mixture", "n: number of participants in each group", "group 3: CC with herbal mixture", "participants", "groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 1: CC", "group 2: herbal mixture", "n: number of participants in each group", "group 3: CC with herbal mixture", "participants", "groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 1: CC", "group 2: herbal mixture", "n: number of participants in each group", "group 3: CC with herbal mixture", "participants", "groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 1: CC", "group 2: herbal mixture", "n: number of participants in each group", "group 3: CC with herbal mixture", "participants", "groups"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["CYP enzyme activity", "liver"], "gold": ["CYP enzyme activity"], "text": "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48]."}, {"generated": ["HepaRG cell line", "hepatocellular carcinoma", "liver-specific enzymes"], "gold": ["liver-specific enzymes"], "text": "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7]."}, {"generated": ["HepaRG cell line", "hepatocellular carcinoma", "liver-specific enzymes"], "gold": ["liver-specific enzymes"], "text": "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7]."}, {"generated": ["BNPP", "\u00b5g/mL", "PNS"], "gold": ["BNPP"], "text": "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL)."}, {"generated": ["BNPP", "\u00b5g/mL", "PNS"], "gold": ["BNPP"], "text": "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL)."}, {"generated": ["cytochrome P450 enzymes", "drug transporters", "CYPs"], "gold": [], "text": "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates."}, {"generated": ["cytochrome P450 enzymes", "drug transporters", "CYPs"], "gold": [], "text": "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates."}, {"generated": ["cytochrome P450 enzymes", "drug transporters", "CYPs"], "gold": [], "text": "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates."}, {"generated": ["MDCKII parental cell line", "pheophorbide A", "MDCKII-BCRP cells", "BCRP inhibition", "flow cytometry", "BCRP substrate"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["MDCKII parental cell line", "pheophorbide A", "MDCKII-BCRP cells", "BCRP inhibition", "flow cytometry", "BCRP substrate"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["MDCKII parental cell line", "pheophorbide A", "MDCKII-BCRP cells", "BCRP inhibition", "flow cytometry", "BCRP substrate"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["MDCKII parental cell line", "pheophorbide A", "MDCKII-BCRP cells", "BCRP inhibition", "flow cytometry", "BCRP substrate"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["MDCKII parental cell line", "pheophorbide A", "MDCKII-BCRP cells", "BCRP inhibition", "flow cytometry", "BCRP substrate"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["MDCKII parental cell line", "pheophorbide A", "MDCKII-BCRP cells", "BCRP inhibition", "flow cytometry", "BCRP substrate"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["evaluated data", "as described", "previous [28]", "previous"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["evaluated data", "as described", "previous [28]", "previous"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["evaluated data", "as described", "previous [28]", "previous"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["evaluated data", "as described", "previous [28]", "previous"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["pharmacokinetic parameters", "DAS 25 mg/kg P.O."], "gold": [], "text": "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O."}, {"generated": ["pharmacokinetic parameters", "DAS 25 mg/kg P.O."], "gold": [], "text": "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O."}, {"generated": ["intestinal BCRP/ABCG2 protein expression", "Hepatic BCRP/ABCG2 protein expression", "APG pretreatment", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["intestinal BCRP/ABCG2 protein expression", "Hepatic BCRP/ABCG2 protein expression", "APG pretreatment", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["intestinal BCRP/ABCG2 protein expression", "Hepatic BCRP/ABCG2 protein expression", "APG pretreatment", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["intestinal BCRP/ABCG2 protein expression", "Hepatic BCRP/ABCG2 protein expression", "APG pretreatment", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["tumor cell angiogenesis", "reactive oxygen species production"], "gold": [], "text": "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124]."}, {"generated": ["tumor cell angiogenesis", "reactive oxygen species production"], "gold": [], "text": "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124]."}, {"generated": ["Table S4"], "gold": [], "text": "Table S4."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "50 donors", "dextrorphan-d", "Pooled human liver microsomes (HLMs", "\u03b2-estradiol (E2)", "mixed gender", "E/Z)-endoxifen hydrochloride"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "50 donors", "dextrorphan-d", "Pooled human liver microsomes (HLMs", "\u03b2-estradiol (E2)", "mixed gender", "E/Z)-endoxifen hydrochloride"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "50 donors", "dextrorphan-d", "Pooled human liver microsomes (HLMs", "\u03b2-estradiol (E2)", "mixed gender", "E/Z)-endoxifen hydrochloride"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "50 donors", "dextrorphan-d", "Pooled human liver microsomes (HLMs", "\u03b2-estradiol (E2)", "mixed gender", "E/Z)-endoxifen hydrochloride"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "50 donors", "dextrorphan-d", "Pooled human liver microsomes (HLMs", "\u03b2-estradiol (E2)", "mixed gender", "E/Z)-endoxifen hydrochloride"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "50 donors", "dextrorphan-d", "Pooled human liver microsomes (HLMs", "\u03b2-estradiol (E2)", "mixed gender", "E/Z)-endoxifen hydrochloride"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "50 donors", "dextrorphan-d", "Pooled human liver microsomes (HLMs", "\u03b2-estradiol (E2)", "mixed gender", "E/Z)-endoxifen hydrochloride"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["Eng et al.", "2016"], "gold": [], "text": "2016; Eng et\u00a0al."}, {"generated": ["Eng et al.", "2016"], "gold": [], "text": "2016; Eng et\u00a0al."}, {"generated": ["physiological or medical parameters", "Table 2", "pharmacology"], "gold": [], "text": "9, Table\u00a02)."}, {"generated": ["physiological or medical parameters", "Table 2", "pharmacology"], "gold": [], "text": "9, Table\u00a02)."}, {"generated": ["physiological or medical parameters", "Table 2", "pharmacology"], "gold": [], "text": "9, Table\u00a02)."}, {"generated": ["competitive, noncompetitive and mixed\u2010inhibition models", "Equations 1\u20133"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["competitive, noncompetitive and mixed\u2010inhibition models", "Equations 1\u20133"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["microsomes incubation", "CYP", "TM", "activity", "VKOR", "Western blot", "Real Time-Polymerase Chain Reaction", "protein expression", "mRNA expression"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["Racemic warfarin", "diclofenac sodium", "naringin"], "gold": [], "text": "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA)."}, {"generated": ["Racemic warfarin", "diclofenac sodium", "naringin"], "gold": [], "text": "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA)."}, {"generated": ["Racemic warfarin", "diclofenac sodium", "naringin"], "gold": [], "text": "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA)."}, {"generated": ["warfarin"], "gold": [], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": ["5\u2032-methoxydehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "cadina-4,10(15)-dien-3-one", "dehydro-b-peltatin methyl ether", "lignans", "4\u2032-demethyldesoxypodophyllotoxin", "dehydropodophyllotoxin", "beta-Sitosterol"], "gold": [], "text": "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica."}, {"generated": ["5\u2032-methoxydehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "cadina-4,10(15)-dien-3-one", "dehydro-b-peltatin methyl ether", "lignans", "4\u2032-demethyldesoxypodophyllotoxin", "dehydropodophyllotoxin", "beta-Sitosterol"], "gold": [], "text": "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica."}, {"generated": ["5\u2032-methoxydehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "cadina-4,10(15)-dien-3-one", "dehydro-b-peltatin methyl ether", "lignans", "4\u2032-demethyldesoxypodophyllotoxin", "dehydropodophyllotoxin", "beta-Sitosterol"], "gold": [], "text": "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica."}, {"generated": ["5\u2032-methoxydehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "cadina-4,10(15)-dien-3-one", "dehydro-b-peltatin methyl ether", "lignans", "4\u2032-demethyldesoxypodophyllotoxin", "dehydropodophyllotoxin", "beta-Sitosterol"], "gold": [], "text": "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica."}, {"generated": ["5\u2032-methoxydehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "cadina-4,10(15)-dien-3-one", "dehydro-b-peltatin methyl ether", "lignans", "4\u2032-demethyldesoxypodophyllotoxin", "dehydropodophyllotoxin", "beta-Sitosterol"], "gold": [], "text": "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica."}, {"generated": ["5\u2032-methoxydehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "cadina-4,10(15)-dien-3-one", "dehydro-b-peltatin methyl ether", "lignans", "4\u2032-demethyldesoxypodophyllotoxin", "dehydropodophyllotoxin", "beta-Sitosterol"], "gold": [], "text": "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica."}, {"generated": ["5\u2032-methoxydehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "cadina-4,10(15)-dien-3-one", "dehydro-b-peltatin methyl ether", "lignans", "4\u2032-demethyldesoxypodophyllotoxin", "dehydropodophyllotoxin", "beta-Sitosterol"], "gold": [], "text": "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica."}, {"generated": ["5\u2032-methoxydehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "cadina-4,10(15)-dien-3-one", "dehydro-b-peltatin methyl ether", "lignans", "4\u2032-demethyldesoxypodophyllotoxin", "dehydropodophyllotoxin", "beta-Sitosterol"], "gold": [], "text": "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica."}, {"generated": ["protective effect", "dose-dependent"], "gold": [], "text": "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015)."}, {"generated": ["protective effect", "dose-dependent"], "gold": [], "text": "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015)."}, {"generated": ["Food and water"], "gold": [], "text": "Food and water were supplied ad libitum."}, {"generated": ["n = 6", "\u00b1 S. D.", "mean"], "gold": [], "text": "Data are expressed as mean \u00b1 S. D. (n = 6)."}, {"generated": ["n = 6", "\u00b1 S. D.", "mean"], "gold": [], "text": "Data are expressed as mean \u00b1 S. D. (n = 6)."}, {"generated": ["n = 6", "\u00b1 S. D.", "mean"], "gold": [], "text": "Data are expressed as mean \u00b1 S. D. (n = 6)."}, {"generated": ["ginkgolic acid content"], "gold": [], "text": "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154]."}], "FN": [{"generated": [], "gold": ["dopamine levels"], "text": "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25]."}, {"generated": [], "gold": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "text": "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043)."}, {"generated": [], "gold": ["rs1142345"], "text": "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs."}, {"generated": ["extensive metabolizer", "AUC", "concentration-time curve", "poor metabolizer"], "gold": ["AUC: concentration-time curve"], "text": "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer."}, {"generated": [], "gold": ["bioavailability", "bioavailable concentration"], "text": "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract."}, {"generated": [], "gold": ["bioavailability", "bioavailable concentration"], "text": "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract."}, {"generated": [], "gold": ["OATs", "SLC22"], "text": "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs."}, {"generated": [], "gold": ["OATs", "SLC22"], "text": "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs."}, {"generated": [], "gold": ["Oat3", "Oat1"], "text": "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7]."}, {"generated": [], "gold": ["Oat3", "Oat1"], "text": "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7]."}, {"generated": [], "gold": ["the OATs", "transporter families"], "text": "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly."}, {"generated": [], "gold": ["the OATs", "transporter families"], "text": "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly."}, {"generated": [], "gold": ["CL/Fs"], "text": "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively."}, {"generated": ["Antinuclear antibody (ANA)", "smooth muscle antibody"], "gold": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "text": "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80."}, {"generated": [], "gold": ["periportal hepatocyte"], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": [], "gold": ["maximum plasma concentration (Cmax)", "area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)"], "text": "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax)."}, {"generated": [], "gold": ["maximum plasma concentration (Cmax)", "area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)"], "text": "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax)."}, {"generated": [], "gold": ["maximum plasma concentration (Cmax)", "area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)"], "text": "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax)."}, {"generated": [], "gold": ["AUC0\u2013\u221e", "Cmax", "t1/2"], "text": "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea)."}, {"generated": [], "gold": ["AUC0\u2013\u221e", "Cmax", "t1/2"], "text": "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea)."}, {"generated": [], "gold": ["AUC0\u2013\u221e", "Cmax", "t1/2"], "text": "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea)."}, {"generated": [], "gold": ["AUC0\u2013\u221e"], "text": "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3."}, {"generated": [], "gold": ["AUC"], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": [], "gold": ["AUC"], "text": "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin."}, {"generated": ["categorical variables", "ratios", "baseline characteristics", "mean \u00b1 SD", "continuous variables"], "gold": ["AUC"], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": [], "gold": ["Biliary excretion", "urinary excretion"], "text": "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group."}, {"generated": [], "gold": ["Biliary excretion", "urinary excretion"], "text": "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group."}, {"generated": [], "gold": ["AUC"], "text": "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection."}, {"generated": [], "gold": ["blood pressure", "heart rhythm"], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": [], "gold": ["blood pressure", "heart rhythm"], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": [], "gold": ["cytochrome P450 (P450)", "monooxygenase forms"], "text": "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013)."}, {"generated": [], "gold": ["cytochrome P450 (P450)", "monooxygenase forms"], "text": "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013)."}, {"generated": [], "gold": ["nuclear receptor"], "text": "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016)."}, {"generated": [], "gold": ["DMSO"], "text": "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO."}, {"generated": [], "gold": ["Potential TDI of P450 enzyme activity", "NADPH", "IC50"], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": [], "gold": ["Potential TDI of P450 enzyme activity", "NADPH", "IC50"], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": [], "gold": ["Potential TDI of P450 enzyme activity", "NADPH", "IC50"], "text": "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH."}, {"generated": [], "gold": ["the concentration-response (percentage control value)", "the IC50 values"], "text": "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq."}, {"generated": [], "gold": ["the concentration-response (percentage control value)", "the IC50 values"], "text": "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq."}, {"generated": [], "gold": ["logIC50", "logEC50"], "text": "2 above (substituting logEC50 for logIC50)."}, {"generated": [], "gold": ["logIC50", "logEC50"], "text": "2 above (substituting logEC50 for logIC50)."}, {"generated": [], "gold": ["IC50"], "text": "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml)."}, {"generated": [], "gold": ["CYP2C19, CYP3A4, CYP2D6, and CYP2C9", "P450"], "text": "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9."}, {"generated": [], "gold": ["CYP2C19, CYP3A4, CYP2D6, and CYP2C9", "P450"], "text": "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9."}, {"generated": [], "gold": ["plasma concentrations for these compounds"], "text": "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract."}, {"generated": [], "gold": ["in vivo concentration", "IC50"], "text": "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans."}, {"generated": [], "gold": ["in vivo concentration", "IC50"], "text": "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans."}, {"generated": [], "gold": ["phase II drug-metabolizing enzymes"], "text": "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes."}, {"generated": [], "gold": ["bioavailability", "bioavailable concentration"], "text": "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract."}, {"generated": [], "gold": ["bioavailability", "bioavailable concentration"], "text": "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract."}, {"generated": [], "gold": ["clearance", "area-under-the-curve"], "text": "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance."}, {"generated": [], "gold": ["clearance", "area-under-the-curve"], "text": "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance."}, {"generated": [], "gold": ["AUC0\u2013\u221e"], "text": "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %."}, {"generated": [], "gold": ["Cmax", "tmax"], "text": "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination."}, {"generated": [], "gold": ["Cmax", "tmax"], "text": "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination."}, {"generated": [], "gold": ["CL/F", "T1/2"], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": [], "gold": ["CL/F", "T1/2"], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": [], "gold": ["the PR interval", "corrected QT interval (QTc)", "QRS duration"], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": [], "gold": ["the PR interval", "corrected QT interval (QTc)", "QRS duration"], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": [], "gold": ["the PR interval", "corrected QT interval (QTc)", "QRS duration"], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": [], "gold": ["LDL (low density lipoprotein)", "HDL (high density lipoprotein)"], "text": "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time."}, {"generated": [], "gold": ["LDL (low density lipoprotein)", "HDL (high density lipoprotein)"], "text": "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time."}, {"generated": [], "gold": ["International normalized ratio"], "text": "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser."}, {"generated": [], "gold": ["clotting time"], "text": "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "apparent volume of distribution (V/F)", "half-life", "kel", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": ["CL/F", "half-life", "AUC0\u2212\u221e", "CL/kel"], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "INR data", "time data", "S-warfarin concentration"], "gold": ["INR", "prothrombin complex activity (PCA"], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "INR data", "time data", "S-warfarin concentration"], "gold": ["INR", "prothrombin complex activity (PCA"], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["Cmax (\u03bcg\u2009mL\u22121)", "CL/F (mL\u2009h\u22121)", "tmax (h)", "Fraction unbound (fu)", "t1/2 (h)", "AUC (\u03bcg\u2009mL\u22121\u2009h)"], "gold": ["Cmax", "Cmax, maximum concentration", "F, bioavailability", "CL/F, apparent clearance", "AUC", "CL, clearance", "t1/2", "CL/F", "tmax, time to Cmax", "AUC, area under the plasma concentration\u2013time curve", "tmax"], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": [], "gold": ["AUC"], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": [], "gold": ["bioavailability"], "text": "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data."}, {"generated": [], "gold": ["LVEF"], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": ["antithrombotic drugs", "diabetes mellitus", "Pap smears", "endometrial cancer", "endometrial hyperplasia", "red ginseng products", "functional foods", "horseradish", "flaxseed", "menopausal", "sex hormone\u2013related cancers", "selective estrogen receptor modulators", "other clinical trials", "plant hormones", "sleep inducers", "thromboembolism", "migraines", "white sorghum", "antihyperlipidemic drugs", "bisphosphonates", "cardiovascular disease", "chemotherapy", "creatinine", "antidepressants", "alanine aminotransferase (ALT)", "breast cancer", "calcitonin", "cerebrovascular disease", "hysterectomy", "mammographies", "hypertension", "pomegranate", "herbal medicines", "women", "surgery", "female hormone formulations", "BI-RADS Category 0", "thyroid", "clinically significant abnormalities", "BI-RADS Category 1-3", "intensive exercises", "red shamrock", "aspartate aminotransferase (AST)"], "gold": ["alanine aminotransferase (ALT)", "cholesterol", "creatinine", "aspartate aminotransferase (AST)", "fasting blood sugar", "triglyceride"], "text": "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study."}, {"generated": [], "gold": ["AUC: area under the plasma"], "text": "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats."}, {"generated": [], "gold": ["efficacy and safety"], "text": "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14]."}, {"generated": [], "gold": ["glutathione peroxidase (GPx)", "catalase (CAT)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"], "text": "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3]."}, {"generated": [], "gold": ["glutathione peroxidase (GPx)", "catalase (CAT)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"], "text": "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3]."}, {"generated": [], "gold": ["glutathione peroxidase (GPx)", "catalase (CAT)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"], "text": "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3]."}, {"generated": [], "gold": ["glutathione peroxidase (GPx)", "catalase (CAT)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"], "text": "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3]."}, {"generated": [], "gold": ["insulin", "blood glucose"], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": [], "gold": ["insulin", "blood glucose"], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": [], "gold": ["SOD", "CAT", "MDA"], "text": "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19]."}, {"generated": [], "gold": ["SOD", "CAT", "MDA"], "text": "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19]."}, {"generated": [], "gold": ["SOD", "CAT", "MDA"], "text": "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19]."}, {"generated": [], "gold": ["HOMA-IR level", "FBS level", "insulin level"], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": [], "gold": ["HOMA-IR level", "FBS level", "insulin level"], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": [], "gold": ["HOMA-IR level", "FBS level", "insulin level"], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": [], "gold": ["SOD", "GPx", "CAT", "MDA"], "text": "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17]."}, {"generated": [], "gold": ["SOD", "GPx", "CAT", "MDA"], "text": "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17]."}, {"generated": [], "gold": ["SOD", "GPx", "CAT", "MDA"], "text": "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17]."}, {"generated": [], "gold": ["SOD", "GPx", "CAT", "MDA"], "text": "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17]."}, {"generated": [], "gold": ["FBS level"], "text": "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56]."}, {"generated": [], "gold": ["blood counts", "CD4+ T-cell count"], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": [], "gold": ["blood counts", "CD4+ T-cell count"], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": [], "gold": ["CD4+ T-cell count"], "text": "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3."}, {"generated": [], "gold": ["HIV-1 RNA load"], "text": "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study."}, {"generated": [], "gold": ["C\u03c4", "AUC\u03c4"], "text": "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively."}, {"generated": [], "gold": ["C\u03c4", "AUC\u03c4"], "text": "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively."}, {"generated": [], "gold": ["CYP enzymes"], "text": "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions."}, {"generated": [], "gold": ["CYP2C9", "CYP1A2"], "text": "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28]."}, {"generated": [], "gold": ["CYP2C9", "CYP1A2"], "text": "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28]."}, {"generated": [], "gold": ["CYP2C19 activity"], "text": "does not affect CYP2C19 activity when administered over an 8-day period."}, {"generated": [], "gold": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "text": "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin."}, {"generated": [], "gold": ["PK-PD parameters"], "text": "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin."}, {"generated": [], "gold": ["CYP2C9"], "text": "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47]."}, {"generated": [], "gold": ["international normalized ratio (INR)", "prothrombin time (PT)", "activated partial thromboplastin time (aPTT)"], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": [], "gold": ["international normalized ratio (INR)", "prothrombin time (PT)", "activated partial thromboplastin time (aPTT)"], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": [], "gold": ["international normalized ratio (INR)", "prothrombin time (PT)", "activated partial thromboplastin time (aPTT)"], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": [], "gold": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "text": "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day."}, {"generated": [], "gold": ["approximate volume used to aid swallowing"], "text": "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable."}, {"generated": [], "gold": ["ADME processes"], "text": "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms."}, {"generated": [], "gold": ["intestinal glucuronidation"], "text": "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction."}, {"generated": [], "gold": ["oral bioavailability"], "text": "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365]."}, {"generated": [], "gold": ["clearance"], "text": "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70]."}, {"generated": [], "gold": ["an elimination half-life"], "text": "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12]."}, {"generated": [], "gold": ["Liver drug enzymes"], "text": "Liver drug enzymes are the common sites of drug interaction in human."}, {"generated": [], "gold": ["PON"], "text": "The influence test for PON was conducted by the method of Furlong et al."}, {"generated": [], "gold": ["Total RNA"], "text": "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China)."}, {"generated": [], "gold": ["bioavailability"], "text": "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17]."}, {"generated": [], "gold": ["Cmax", "AUC(0,\u221e)"], "text": "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion."}, {"generated": [], "gold": ["Cmax", "AUC(0,\u221e)"], "text": "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion."}, {"generated": [], "gold": ["blood pressure", "heart rate", "body temperature"], "text": "No clinically significant alterations in blood pressure, heart rate or body temperature were observed."}, {"generated": [], "gold": ["blood pressure", "heart rate", "body temperature"], "text": "No clinically significant alterations in blood pressure, heart rate or body temperature were observed."}, {"generated": [], "gold": ["blood pressure", "heart rate", "body temperature"], "text": "No clinically significant alterations in blood pressure, heart rate or body temperature were observed."}, {"generated": [], "gold": ["quadriceps muscle strength (QMS)", "lactate"], "text": "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women."}, {"generated": [], "gold": ["quadriceps muscle strength (QMS)", "lactate"], "text": "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women."}, {"generated": [], "gold": ["lactate level"], "text": "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions."}, {"generated": [], "gold": ["muscle strength"], "text": "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength."}, {"generated": [], "gold": ["BMI"], "text": "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1)."}, {"generated": [], "gold": ["lactate level"], "text": "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2."}, {"generated": [], "gold": ["lactate"], "text": "have shown the association between high lactate production and reduced oxidative metabolism [47]."}, {"generated": [], "gold": ["bioavailability"], "text": "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["CD3+", "platelets", "antibody production", "delayed hypersensitivity", "caspase 3 expression", "T cell apoptosis", "CD4", "Bax expression", "CD4+ T cells", "NK cells", "cell cycle arrest", "caspase 8 activity", "caspase 3 activity", "tumor inhibition", "apoptotic rate", "bone marrow cells", "phagocytic activity", "CD4/CD8"], "gold": ["CD3+", "WBC", "platelets", "antibody production", "T cell apoptosis", "CD4", "cells count", "CD8", "Bax expression", "CD4+ T cells", "NK cells", "caspase 3", "caspase 3 activity", "bone marrow cells", "phagocytic activity"], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": [], "gold": ["lipid peroxide levels", "superoxide dismutase (SOD)", "suppressor T cells"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": [], "gold": ["lipid peroxide levels", "superoxide dismutase (SOD)", "suppressor T cells"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": [], "gold": ["lipid peroxide levels", "superoxide dismutase (SOD)", "suppressor T cells"], "text": "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131]."}, {"generated": [], "gold": ["blood glucose level"], "text": "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study."}, {"generated": [], "gold": ["Glucose level"], "text": "Glucose level was determined using GOD-POD Erba diagnostic kits."}, {"generated": [], "gold": ["BUN"], "text": "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig."}, {"generated": [], "gold": ["INR", "monitoring"], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": [], "gold": ["INR", "monitoring"], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": [], "gold": ["thrombin times (TTs)"], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": [], "gold": ["blood pressure"], "text": "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner."}, {"generated": [], "gold": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "Cholesterol", "LDL-C"], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": [], "gold": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "Cholesterol", "LDL-C"], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": [], "gold": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "Cholesterol", "LDL-C"], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": [], "gold": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "Cholesterol", "LDL-C"], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": [], "gold": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "Cholesterol", "LDL-C"], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": [], "gold": ["HDL-C", "total cholesterol", "cholesterol", "triglycerides", "Cholesterol", "LDL-C"], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": [], "gold": ["total cholesterol"], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": [], "gold": ["adipocyte differentiation", "blood viscosity", "myocardial mass", "ERK", "PI3-K/Akt", "cyclooxygenase inhibitory activity", "calcium influx"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["adipocyte differentiation", "blood viscosity", "myocardial mass", "ERK", "PI3-K/Akt", "cyclooxygenase inhibitory activity", "calcium influx"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["adipocyte differentiation", "blood viscosity", "myocardial mass", "ERK", "PI3-K/Akt", "cyclooxygenase inhibitory activity", "calcium influx"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["adipocyte differentiation", "blood viscosity", "myocardial mass", "ERK", "PI3-K/Akt", "cyclooxygenase inhibitory activity", "calcium influx"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["adipocyte differentiation", "blood viscosity", "myocardial mass", "ERK", "PI3-K/Akt", "cyclooxygenase inhibitory activity", "calcium influx"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["adipocyte differentiation", "blood viscosity", "myocardial mass", "ERK", "PI3-K/Akt", "cyclooxygenase inhibitory activity", "calcium influx"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["adipocyte differentiation", "blood viscosity", "myocardial mass", "ERK", "PI3-K/Akt", "cyclooxygenase inhibitory activity", "calcium influx"], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": [], "gold": ["electrolyte levels"], "text": "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects."}, {"generated": [], "gold": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"], "text": "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability."}, {"generated": [], "gold": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"], "text": "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability."}, {"generated": [], "gold": ["NADPH"], "text": "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA)."}, {"generated": [], "gold": ["K m values", "concentrations of substrates"], "text": "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting."}, {"generated": [], "gold": ["K m values", "concentrations of substrates"], "text": "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting."}, {"generated": [], "gold": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"], "text": "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients)."}, {"generated": [], "gold": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"], "text": "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients)."}, {"generated": [], "gold": ["CYP"], "text": "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates."}, {"generated": [], "gold": ["PT time"], "text": "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32]."}, {"generated": [], "gold": ["bioavailability"], "text": "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB."}, {"generated": [], "gold": ["Fifty percent inhibitory concentration"], "text": "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations."}, {"generated": [], "gold": ["IC"], "text": "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb."}, {"generated": [], "gold": ["serum human chorionic gonadotropin"], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": [], "gold": ["bioavailability"], "text": "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability."}, {"generated": [], "gold": ["Platelet aggregation"], "text": "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate."}, {"generated": [], "gold": ["Cmax"], "text": "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121."}, {"generated": [], "gold": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"], "text": "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve."}, {"generated": [], "gold": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"], "text": "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve."}, {"generated": [], "gold": ["BIO", "AUC"], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": [], "gold": ["BIO", "AUC"], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": [], "gold": ["MCF-7 and T-47D cell growth"], "text": "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010)."}, {"generated": [], "gold": ["cell growth", "cell viability"], "text": "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012)."}, {"generated": [], "gold": ["cell growth", "cell viability"], "text": "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012)."}, {"generated": [], "gold": ["glutathione concomitant", "TBARS", "liver transaminases", "antioxidant enzymes", "the activity of sGPT and sGOT"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": [], "gold": ["glutathione concomitant", "TBARS", "liver transaminases", "antioxidant enzymes", "the activity of sGPT and sGOT"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": [], "gold": ["glutathione concomitant", "TBARS", "liver transaminases", "antioxidant enzymes", "the activity of sGPT and sGOT"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": [], "gold": ["glutathione concomitant", "TBARS", "liver transaminases", "antioxidant enzymes", "the activity of sGPT and sGOT"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": [], "gold": ["glutathione concomitant", "TBARS", "liver transaminases", "antioxidant enzymes", "the activity of sGPT and sGOT"], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": [], "gold": ["protein expression levels"], "text": "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009)."}, {"generated": [], "gold": ["CHO", "AUC"], "text": "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001)."}, {"generated": [], "gold": ["CHO", "AUC"], "text": "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001)."}, {"generated": [], "gold": ["Total Energy Expenditure (TEE)"], "text": "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3)."}, {"generated": [], "gold": ["bioavailability"], "text": "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion."}, {"generated": [], "gold": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"], "text": "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA)."}, {"generated": [], "gold": ["anesthesia"], "text": "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane."}, {"generated": [], "gold": ["AUC"], "text": "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88]."}, {"generated": [], "gold": ["serum creatinine level"], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": [], "gold": ["serum creatinine level"], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": [], "gold": ["AUC"], "text": "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil."}, {"generated": [], "gold": ["CYP"], "text": "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207]."}, {"generated": [], "gold": ["platelet aggregation"], "text": "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234]."}, {"generated": [], "gold": ["AUC"], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": [], "gold": ["individual susceptibility"], "text": "The clinical significance of this phenomenon depends on individual susceptibility."}, {"generated": [], "gold": ["blood sugar"], "text": "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels."}, {"generated": [], "gold": ["CYP2D6", "CYP3A"], "text": "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996)."}, {"generated": [], "gold": ["CYP2D6", "CYP3A"], "text": "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996)."}]}